Quanterix Corp. (QTRX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Quanterix Corporation is a life sciences company focused on ultra-sensitive protein biomarker detection (Simoa technology) and spatial biology solutions (following the acquisition of Akoya Biosciences in July 2025). The company operates as a single reportable segment, selling instruments, consumables, and services to research, academic, and biopharmaceutical customers globally.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $36.4 million | $30.3 million |
| Gross Profit | $15.6 million (43% margin) | $14.8 million (49% margin) |
| Net Loss | $(17.5) million | $(20.5) million |
| Loss Per Share (Basic/Diluted) | $(0.37) | $(0.53) |
| Cash & Cash Equivalents | $36.2 million | $76.5 million |
| Marketable Securities | $63.1 million | $88.4 million |
| Total Liquidity | $99.3 million | $164.9 million |
| Operating Cash Flow | $(18.1) million | $(13.9) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20% year-over-year, driven primarily by the inclusion of Akoya Biosciences ($8.7M product, $3.7M service revenue). Legacy Quanterix product revenue declined 19% due to reduced U.S. federal research funding and macroeconomic headwinds.
- Impairment Charge: The company recorded a non-cash impairment charge of $19.8 million related to In-Process Research and Development (IPR&D) assets. This resulted from the termination of a diagnostics development agreement assumed in the Akoya acquisition.
- One-Time Income: The termination of the same development agreement generated $21.6 million in one-time income (recorded in "Other income, net"), consisting of $13.7 million from the reversal of an off-market liability and $7.9 million from deferred revenue.
- Operating Expenses: R&D expenses decreased 27% and SG&A decreased 4% compared to Q1 2025, reflecting cost synergies from the Akoya acquisition and restructuring actions taken in 2025.
- Accounting Change: Shipping and handling costs were reclassified from SG&A to Cost of Product Revenue, applied retrospectively.
Guidance, Outlook, and Risks
- Strategic Shift: Following a new CEO appointment in January 2026, management is streamlining the product roadmap to focus on Alzheimer's diagnostics and commercial effectiveness. The company aims to pursue FDA IVD status for its HD-X platform in 2027.
- Cash Flow Outlook: Management expects to achieve cash flow breakeven in the second half of 2026, contingent on successful implementation of strategy changes and revenue targets.
- Regulatory Milestones: A 510(k) submission for a multi-analyte blood test for Alzheimer's disease was made to the FDA in January 2026. Medicare reimbursement for the LucentAD Complete test was approved at $897 in November 2025.
- Risks: Continued reliance on federal research funding, macroeconomic uncertainty affecting capital spending, and the integration risks associated with the Akoya acquisition. The company maintains a valuation allowance on the majority of its deferred tax assets.
Investor Verification Checklist
- Recurring Revenue Quality: Verify the sustainability of the 20% revenue growth given the 19% decline in legacy Quanterix product revenue and the one-time nature of the $21.6M income.
- IPR&D Impairment: Confirm that the $19.8M impairment charge is fully resolved and will not recur, as it was tied to a specific terminated contract.
- Liquidity Runway: Assess the burn rate against the $99.3M liquidity position to validate the "cash flow breakeven in H2 2026" guidance.
- Alzheimer's Pipeline: Monitor the progress of the 510(k) submission and the commercial rollout of the LucentAD Complete test following Medicare pricing approval.
- Contingent Liabilities: Review the fair value adjustments of the Emission earnout and Akoya contingent liabilities, which fluctuated by $1.5M in the quarter.